Engineered plasma cells show long-lasting antileukemic activity in mice

Researchers show for the first time that engineered human plasma B cells can be used to treat a disease—specifically leukemia—in a humanized animal model. The results mark a key step in the realization of ePCs as therapies to treat cancer, auto-immune disorders, and protein deficiency disorders. The results appear July 2 in the journal Molecular Therapy.

​Medical Xpress – latest medical and health news stories

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *